Applied Therapeutics Future Growth
Future criteria checks 2/6
Applied Therapeutics is forecast to grow earnings and revenue by 15.8% and 49.4% per annum respectively while EPS is expected to grow by 25.2% per annum.
Key information
15.8%
Earnings growth rate
25.2%
EPS growth rate
| Biotechs earnings growth | 24.9% |
| Revenue growth rate | 49.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Apr 2025 |
Recent future growth updates
Recent updates
Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Nov 15
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 61 | N/A | N/A | N/A | 1 |
| 12/31/2026 | 38 | -73 | N/A | N/A | 3 |
| 12/31/2025 | 8 | -129 | N/A | N/A | 4 |
| 12/31/2024 | 0 | -106 | -84 | -84 | N/A |
| 9/30/2024 | 0 | -187 | -82 | -82 | N/A |
| 6/30/2024 | 0 | -161 | -73 | -73 | N/A |
| 3/31/2024 | 0 | -194 | -67 | -67 | N/A |
| 12/31/2023 | 10 | -120 | -55 | -55 | N/A |
| 9/30/2023 | 11 | -97 | -54 | -54 | N/A |
| 6/30/2023 | 11 | -73 | -59 | -59 | N/A |
| 3/31/2023 | 11 | -70 | -61 | -61 | N/A |
| 12/31/2022 | N/A | -83 | -78 | -78 | N/A |
| 9/30/2022 | N/A | -95 | -89 | -89 | N/A |
| 6/30/2022 | N/A | -105 | -85 | -85 | N/A |
| 3/31/2022 | N/A | -105 | -93 | -93 | N/A |
| 12/31/2021 | N/A | -106 | -91 | -91 | N/A |
| 9/30/2021 | N/A | -102 | -87 | -87 | N/A |
| 6/30/2021 | N/A | -104 | -92 | -92 | N/A |
| 3/31/2021 | N/A | -106 | -82 | -82 | N/A |
| 12/31/2020 | N/A | -94 | -78 | -78 | N/A |
| 9/30/2020 | N/A | -88 | -68 | -68 | N/A |
| 6/30/2020 | N/A | -69 | -55 | -55 | N/A |
| 3/31/2020 | N/A | -49 | -48 | -48 | N/A |
| 12/31/2019 | N/A | -46 | -36 | -36 | N/A |
| 9/30/2019 | N/A | -35 | -30 | -30 | N/A |
| 6/30/2019 | N/A | -28 | -24 | -24 | N/A |
| 3/31/2019 | N/A | -23 | -17 | -17 | N/A |
| 12/31/2018 | N/A | -17 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APLT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APLT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APLT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APLT's revenue (49.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: APLT's revenue (49.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APLT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 15:49 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Applied Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Carter Gould | Barclays |
| Paul Choi | Goldman Sachs |